Identification of miRNA-Based Signature as a Novel Potential Prognostic Biomarker in Patients with Breast Cancer

Figure 2

OS/RFS miRNAs predict the signature performance in breast cancer patients. Kaplan-Meier curves of the low- and high-risk groups divided by the 17-miRNA-based OS-predictive signature in the training cohort (a) and validation cohort (c). Kaplan-Meier curves of the low- and high-risk groups divided by the 13-miRNA-based RFS-predictive signature in the training cohort (e) and validation cohort (g). ROC curves of the low- and high-risk groups divided by the 17-miRNA-based OS-predictive signature in the training cohort (b) and validation cohort (d). ROC curves of the low- and high-risk groups divided by the 13-miRNA-based RFS-predictive signature in the training cohort (f) and validation cohort (h).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)